Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder

This study has been completed.
Information provided by:
Teva Pharmaceutical Industries Identifier:
First received: February 23, 2004
Last updated: July 12, 2013
Last verified: July 2013
The primary objective of this study is to evaluate the safety and tolerability of Armodafinil (CEP-10953) administered on a flexible-dosage regimen of 100 to 250 mg/day for up to 12 months to patients with excessive sleepiness associated with a current diagnosis of narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS)(regular users of nasal continuous positive airway pressure [nCPAP] therapy), or chronic shift work sleep disorder (SWSD).

Condition Intervention Phase
Sleep Apnea, Obstructive
Sleep Apnea Syndromes
Shift-Work Sleep Disorder
Drug: CEP-10953 (Armodafinil)
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Study of the Safety and Efficacy of CEP-10953 in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period)

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Safety and Tolerability as Measured by Number of Participants With Adverse Events [ Time Frame: Screening/Baseline and months 1, 3, 6, 9, and 12 and every 3 months thereafter ]
    Serious and Non-serious Adverse Events (SAEs). Serious adverse event is any adverse event occurring at any dose that results in any of the following outcomes: death, life-threatening, inpatient hospitalization, persistent or significant disability, congenital anomaly, or an important medical event. An adverse event that does not meet any of the criteria for seriousness listed previously will be regarded as a nonserious adverse event.

Enrollment: 328
Study Start Date: January 2004
Study Completion Date: July 2006
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: CEP-10953 (Armodafinil)
    Armodafinil (po) 100 to 250 mg/day up to 12 months

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients are included in the study if all of the following criteria are met:

  1. Written informed consent is obtained.
  2. Men and women (outpatients) of any ethnic origin, between 18 and 65 years of age (inclusive) are eligible.
  3. The patient has a complaint of excessive sleepiness associated with a current diagnosis of:

    • Narcolepsy-Diagnosis made on the basis of International Classification of Sleep Disorders (ICSD) (American Sleep Disorders Association 2000) criteria.
    • OSAHS-Diagnosis made on the basis of ICSD criteria. Furthermore, patients with OSAHS must meet the following nCPAP therapy requirements:

      • Previous adequate education and intervention efforts to encourage nCPAP therapy use must be documented.
      • A patient's nCPAP therapy regimen must be stable for at least 4 weeks.
      • nCPAP therapy is effective, in the opinion of the investigator.
      • Evidence of regular nCPAP usage must be shown during a 2 week evaluation period (ie, nCPAP therapy usage of at least 4 hours/night on at least 70% of the nights).
    • Chronic SWSD-Diagnosis made on the basis of at least minimum ICSD criteria. Furthermore, patients with chronic SWSD must have had excessive sleepiness during night shifts for at least 3 months, work a minimum of 3 night shifts per month that include at least 6 hours between 2200 and 0800 and are no longer than 12 hours in duration, and plan to continue to work night shifts throughout the study.
  4. The patient has a Clinical Global Impression of Severity of Disease (CGI-S) rating of 4 or more. (For patients with OSAHS, the CGI-S scale will be administered after nCPAP effectiveness and regular usage is established. For patients with narcolepsy or OSAHS, CGI-S will be evaluated to assess general clinical condition. For patients with SWSD, CGI-S will be evaluated to assess sleepiness during the night shift including the commute to and from work.)
  5. The patient is in good health as determined by a medical and psychiatric history, medical examination, electrocardiogram (ECG), serum chemistry and hematology. Women must be surgically sterile, 2 years postmenopausal, or if of childbearing potential, must use a medically accepted method of birth control (ie, barrier method with spermicide, steroidal contraceptive [oral, implanted, and Depo-Provera contraceptives must be used in conjunction with a barrier method], or intrauterine device [IUD]).
  6. The patient may have been prescribed PROVIGIL or stimulant therapy to treat the sleep disorder; however, they must have undergone a washout period of at least 7 days prior to screening assessments.
  7. The patient must be willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol.

Exclusion Criteria:

Patients are excluded from participating in this study if 1 or more of the following criteria are met:

  1. have any clinically significant, uncontrolled medical conditions (treated or untreated)
  2. have a probable diagnosis of a current sleep disorder other than the primary diagnosis of narcolepsy, OSAHS, or chronic SWSD
  3. consume caffeine including coffee, tea and/or other caffeine containing beverages or food averaging more than 600 mg of caffeine or more than 8 cups of coffee per day
  4. used any prescription drugs disallowed by the protocol or clinically significant use of over-the-counter (OTC) drugs within 7 days before the baseline visit
  5. have a history of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, 4th Edition (DSM IV)
  6. have a positive UDS at the screening visit
  7. have a clinically significant deviation from normal in the physical examination
  8. are pregnant or lactating. Any woman becoming pregnant during the study will be withdrawn from the study
  9. have used an investigational drug within 1 month before the screening visit
  10. have any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery)
  11. have a known clinically significant drug sensitivity to stimulants
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00078312

  Show 50 Study Locations
Sponsors and Collaborators
  More Information Identifier: NCT00078312     History of Changes
Other Study ID Numbers: C10953/3023/ES/MN
Study First Received: February 23, 2004
Results First Received: June 1, 2009
Last Updated: July 12, 2013

Keywords provided by Teva Pharmaceutical Industries:
Excessive Sleepiness
Sleep Attacks
Obstructive Sleep Apnea
Obstructive Sleep Hypopnea
Chronic Shift Work Sleep Disorder
Chronic SWSD
Circadian Rhythm Disorder
Shift Worker
Cephalon, Inc

Additional relevant MeSH terms:
Sleep Disorders, Circadian Rhythm
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Sleep Wake Disorders
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Nervous System Diseases
Neurologic Manifestations
Mental Disorders
Disorders of Excessive Somnolence
Chronobiology Disorders
Occupational Diseases
Wakefulness-Promoting Agents
Central Nervous System Stimulants
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers
Molecular Mechanisms of Pharmacological Action processed this record on April 21, 2017